Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
TAKEDA NEW ZEALAND LIMITED,Lanadelumab,Routine prevention of recurrent attacks of hereditary angioedema,Lanadelumab (TAKHZYROÂ®),Options for investment,Community,Respiratory System and Allergies
